Sequence: CTSTRKKQC
| Experiment Id | EXP002118 |
|---|---|
| Paper | Discovery of peptides for ligand-mediated delivery of mRNA lipid nanoparticles to cystic fibrosis lu |
| Peptide | Peptide C |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | |
| Mixing Ratio | N/P = 6 |
| Formulation Format | peptide-lipid functionalized LNP |
| Formulation Components | SM-102/DSPC/Cholesterol/DMG-PEG + peptide-lipid |
| Size Nm | 80.00 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c and Ai9 mice |
| Administration Route | intratracheal |
| Output Type | reporter expression / genome editing |
| Output Value | 3.4-fold higher lung luciferase vs Spikevax; epithelial tdTomato expression |
| Output Units | |
| Output Notes | Robust lung-localized mRNA expression and Cre-mediated genome editing |
| Toxicity Notes | No significant toxicity in vitro or in vivo |
| Curation Notes |